Animal Experiments and Patents Shahnaz Irani Linda Govenlock 11 April 2007.

Slides:



Advertisements
Similar presentations
Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.
Advertisements

Patent Law Overview. Outline Effect of patent protection Effect of patent protection Substantive requirements for patent protection Substantive requirements.
Intellectual Property Fundamentals Ed Genocchio - Principal of Spruson & Ferguson - Mechanical Group Presentation to The Australian Technology Showcase.
The German Experience: Patent litigation and nullification cases
The Paediatric Regulation
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
Disclaimer: The information provided by the USPTO is meant as an educational resource only and should not be construed as legal advice or written law.
Access to medicines – Barriers relating to intellectual property rights and data exclusivity Julian Cockbain & Sigrid Sterckx Yale conference Human rights.
Patent Law Issues in Recent FTAs Joshua D. Sarnoff Washington College of Law American University Washington, DC, USA IP, FTAs,
Necessity is the mother of invention. The father is unknown.
Lauren MacLanahan Office of Technology Licensing GTRC.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Costa Rica Pharma and Biotech Patent Update AIPLA Spring Meeting Seattle, Washington May 2013 Costa Rica Luis Diego Castro Castro.
The Importance and Role of Patent Information Jerusalem 21 June 2010 Andrew Czajkowski Head, Innovation and Technology Support Section.
The Life Sciences Lawyer’s Guide to PTA and PTE
Information Disclosure Statements
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
The Role of Patent Information in Promoting Innovation Islamabad October 8, 2013 Mussadiq Hussain Program Officer, Innovation and Technology Support Section.
11 Indirect Infringement of Patent for Combination of Drugs Kaoru Kuroda, Attorney at Law Abe, Ikubo & Katayama ABE, IKUBO & KATAYAMA.
Subsequent Entry Biologics (SEBs) – Canada Presentation to AIPLA Biotechnology Committee January 25, 2012 Daphne C. Lainson
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
Korean Patent Practice - Pharmaceutical field - Jonghyeok Park MS., Ph.D.course Jonghyeok Park MS., Ph.D.course Partner Pharmacist Patent Attorney.
International IP Issues Federal Lab Consortium Meeting International IP Issues Dr Roisin McNally - European Patent Attorney 20 September 2006.
International Max Planck Research School for Competition and Innovation WIPO – Owais Hassan Shaikh IMPRS-CI 2010 Data Exclusivity Provisions.
Page 1 IOP Genomics Workshop Patents and Patenting Biotech Inventions Annemieke Breukink, Ph.D. September 8th, 2009.
Data exclusivity, patents and registration of medicines Karin Timmermans TWN Regional Workshop Kuala Lumpur on bilateral trade agreements Aug
Patent System In India. Legislative Framework of IP Administration Department of IP &P covers The Patents Act, 1970 (as amended in 2005) The Patents Rules,
2011 Japanese Patent Law Revision AIPLA Annual Meeting October 21, 2011 Yoshi Inaba TMI Associates.
Seminar Industrial Property Protection Prague, 4 June 2003 Patent Protection in Europe Heidrun Krestel Liaison Officer Member States Co-operation Programmes.
PATENT OPPOSITION AND STRATEGY Essenese Obhan, Obhan & Associates.
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Varian Australia Pty Ltd – Some Patenting Issues David Carmichael 6 th May 2004.
Zheng Liu January 18, 2015 Intellectual Property Law For Startups.
Safe Harbor or Not: Application of 271(e)(1) to Pioneering Drug Discovery Activities Susan Steele October 21, 2003.
Summary on Patents Josiah Hernandez.
Promotion of Innovation: Usefulness and value of Patent Information Andrew Czajkowski Head, Innovation and Technology Support Section Ulaanbaatar March.
ADAMS & ADAMS Intellectual Property within the Pharmaceutical Industry Presentation to SAPRAA. 04 September 2009 By : Alexis Apostolidis B.Sc (Chem, Law);
Intellectual Property Laws and Fair Use Guidelines for Educational Multimedia.
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
The Research Use Exception to Patent Infringement Earlier cases Whittemore v. Cutter 29 F. Cas (C.C.D. Mass. 1813) “It could never have been the.
Intellectual Property Rights and Pharmaceutical Industry
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
Biotechnology Chemical Pharmaceutical Customer Partnership
RULES GOVERNING PRIVATE MEMBERS’ LEGISLATIVE PROPOSALS Presentation by NA Table to Committee on Private Members’ Legislative Proposals and Special Petitions.
Derivation Proceedings Gene Quinn Patent Attorney IPWatchdog.com March 27 th, 2012.
TIA IPR Standing Committee Report to TIA Technical Committee “Normative References and IPR” October 21, 2005 Paul Vishny, Chair Dan Bart, TIA.
Lecture 27 Intellectual Property. Intellectual Property simply defined is any form of knowledge or expression created with one's intellect. It includes.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Review of Research-Related Agreements Between Academic Institutions and Other Entities. Manoja Ratnayake Lecamwasam, PhD Intellectual Property and Innovation.
1 Bolar Provisions in Europe Robert Watson Chartered Patent Attorney European Patent Attorney AIPLA, February 2006.
The IOM Template Project: Material Transfer Agreements and Clinical Trial Agreements Presentation to the IOM Forum on Drug Discovery, Development and Translation.
1 IND Applications for Academic Clinical Investigations John Marler, MD US Food and Drug Administration New Hampshire Avenue White Oak, MD
An introduction to Intellectual property protection TG © Copyright by Stevens Institute of Technology.
Technology Transfer Office
SCIENTIFIC & TECHNICAL WRITING Patents
Patent law update.
Biotechnology Chemical Pharmaceutical Customer Partnership
Accelerating your Patent Prosecution in Mexico
Role of IP in facilitating the transfer of technology
Nuts and Bolts of Patent Law
Finding and Understanding Patents
Scope of Supplementary Protection Certificates (SPCs)
Patents, Cannabis, and the Current U.S. Climate
Finding and Understanding Patents
What are the types of intellectual property ?
What are the types of intellectual property?
What You Didn’t Know That You Didn’t Know About Patents
Presentation transcript:

Animal Experiments and Patents Shahnaz Irani Linda Govenlock 11 April 2007

Patents: Basic Facts A standard patent gives the patentee the right to exclude others from exploiting the patented invention including conducting animal experiments A patent application is published 18 months after filing A standard patent has a maximum 20 year term A patent is fundamentally concerned with new and inventive subject matter

Need for experimental data To be granted, a patent application must describe the invention fully. This means there must be sufficient description/examples of the invention For vet/pharma patent applications, the patent specification must generally include results of animal experiments demonstrating drug efficacy/safety/utility

Duplication of data? Patents covering new drug compounds, formulations or indications would generally have original data which was not previously the subject of experimentation Patents can contain comparative experimental data. This could be simply a reference to data published elsewhere. This is not necessarily a duplication of pre-existing experiments.

Delay in publication of data A patent applicant must not publicly disclose their invention-including experimental data-before filing their patent application This delay may result in duplication of experimentation where more than one research group is working on the same invention. This is inevitable Non published data

Data Exclusivity S25A TGA provides that all clinical data provided to obtain regulatory approval of a drug is not available to anyone for 5 years from registration of the drug on the ARTG This includes all Phase l-lll experimental data Phase ll and lll data is rarely included in a patent application Obstructs original/parallel research

Research Exemption Recommendation that an experimental use exemption be introduced into AU Such experimental use includes-determining how an invention works, seeking an improvement of the invention Duplication of experimental data will avoid patent infringement.

Conclusion Duplication of experimentation may be patent infringement Patent applications are published documents Patents per se do not exacerbate needless duplication of animal experiments

Thank you ANY QUESTIONS?